Company intelligence / Profile preview

Northstrive Biosciences

Newport Beach, California, United States

Ownership: Public · ELAB
Development stage: Other

Overview

Northstrive's engineered probiotic candidates (EL-22, EL-32) are in preclinical development for muscle preservation during obesity treatment (with or without GLP-1 receptor agonists), with no active clinical trials reported as of August 2025.

Therapeutic areas: EndocrinologyOther
Modalities: Engineered probioticSmall molecule
Industry: Biotech

Drug pipeline

3 assets

EL-32

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Yuva Biosciences (AI/mitochondrial therapy discovery partnership)

Beyond the preview

Go deeper on Northstrive Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Northstrive Biosciences.

Explore the full profile